Systemic immunoglobulin light chain amyloidosis

G Merlini, A Dispenzieri, V Sanchorawala… - Nature reviews Disease …, 2018 - nature.com
Systemic immunoglobulin light chain amyloidosis is a protein misfolding disease caused by
the conversion of immunoglobulin light chains from their soluble functional states into highly …

Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment

OK Siddiqi, FL Ruberg - Trends in cardiovascular medicine, 2018 - Elsevier
The amyloidoses are a group of systemic diseases characterized by organ deposition of
misfolded protein fragments of diverse origins. The natural history of the disease …

AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: JACC: CardioOncology State-of-the-Art Review

AD Wechalekar, M Fontana, CC Quarta, M Liedtke - Cardio Oncology, 2022 - jacc.org
Amyloid light chain (AL) amyloidosis is a rare, debilitating, often fatal disease. Symptoms of
cardiomyopathy are common presenting features, and patients often are referred to …

[HTML][HTML] Light chain amyloidosis

P Milani, G Merlini, G Palladini - Mediterranean journal of …, 2018 - ncbi.nlm.nih.gov
Light chain (AL) amyloidosis is caused by a usually small plasma-cell clone that is able to
produce the amyloidogenic light chains. They are able to misfold and aggregate, deposit in …

Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018

MA Gertz - Blood cancer journal, 2018 - nature.com
Immunoglobulin light chain amyloidosis (AL) should be considered in any patient that
presents to a cancer care provider with nephrotic range proteinuria, heart failure with …

Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021

M Hasib Sidiqi, MA Gertz - Blood cancer journal, 2021 - nature.com
Immunoglobulin light chain amyloidosis (AL) commonly presents with nephrotic range
proteinuria, heart failure with preserved ejection fraction, nondiabetic peripheral neuropathy …

Advances in the treatment of cardiac amyloidosis

AVS Macedo, PV Schwartzmann… - … treatment options in …, 2020 - Springer
Opinion statement Cardiac amyloidosis is associated with a high mortality rate, a long delay
between the first signs and the diagnosis but a short interval between diagnosis and death …

Copper 64–labeled daratumumab as a PET/CT imaging tracer for multiple myeloma

E Caserta, J Chea, M Minnix, EK Poku… - Blood, The Journal …, 2018 - ashpublications.org
As a growing number of patients with multiple myeloma (MM) respond to upfront therapies
while eventually relapsing in a time frame that is often unpredictable, attention has …

Development and characterization of a prototypic pan-amyloid clearing agent–a novel murine peptide-immunoglobulin fusion

JS Foster, M Balachandran, TJ Hancock… - Frontiers in …, 2023 - frontiersin.org
Introduction Systemic amyloidosis is a progressive disorder characterized by the
extracellular deposition of amyloid fibrils and accessory proteins in visceral organs and …

Systemic amyloidosis: a contemporary overview

V D'Aguanno, M Ralli, M Artico, FY Russo… - Clinical Reviews in …, 2020 - Springer
Amyloidosis constitutes a large spectrum of diseases characterized by an extracellular
deposition of a fibrillar aggregate, generating insoluble and toxic amasses that may be …